ThromboGenics NV, a biotechnology company developing novel medicines for back of the eye diseases and focused on diabetic eye disease, today announced it has strengthened its senior leadership team with the appointment of Susan Schneider, MD, as Chief Medical Officer, and Vinciane Vangeersdaele as Chief Commercial Officer.
Both will be members of the Company’s executive team reporting to ThromboGenics’ CEO, and they will operate from the Company’s offices in Leuven, Belgium and Iselin, New Jersey, US.
Susan Schneider, MD, brings nearly 15 years of experience in clinical drug development to ThromboGenics. Prior to joining ThromboGenics, she was, most recently, Vice President & Therapeutic Area Head of Retina & Glaucoma at Allergan. Susan received her medical degree from the Medical College of Pennsylvania followed by a residency in ophthalmology at the Medical College of Virginia. At ThromboGenics, Dr. Schneider will be responsible for the development and execution of the Company’s global clinical and medical programs that are focused on its industry-leading pipeline of drug candidates targeting diabetic eye disease.
Vinciane Vangeersdaele has recently joined ThromboGenics as Chief Commercial Officer. Vinciane has over 15 years of experience in a variety of sales and marketing leadership roles in the global pharmaceutical industry, the latest being the Head of the Ophthalmology Franchise Europe at Novartis AG. She obtained a master degree in business engineering at the University of Mons-Hainaut. At ThromboGenics, Vinciane will be leading and developing the overall commercial strategy for the Company’s recently formed global JETREA business unit, which was created following ThromboGenics regaining the full global rights to JETREA® from Novartis. She will also be leading the strategic marketing activities for any new compound that emerges from the Company’s clinical development pipeline, which is focused on diabetic eye disease.
Patrik De Haes, MD ThromboGenics CEO, comments: “We are very pleased to welcome Susan and Vinciane to ThromboGenics. I am convinced that their extensive experience will be crucial as we simultaneously progress our pipeline of novel drug candidates targeting diabetic eye disease and develop our commercial plans for JETREA® beyond the US following our recent agreement with Novartis. With our current significant cash resources, a strong clinical pipeline and a first class executive team we are well placed to deliver shareholder value.”
Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.
Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.
There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.